Entera Bio Ltd.
We are a clinical stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. We are initially applying our technology to develop an oral formulation of parathyroid hormone, or PTH, which has been approved in the United States in injectable form for over a decade. Our lead oral PTH product candidate, EB612, has successfully completed a Phase 2a trial for hypoparathyroidism, a rare condition in which the body fails to produce sufficient amounts of PTH. The FDA and the EMA have granted EB612 orphan drug designation for the treatment of hypoparathyroidism.
|Industry:||BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)|
|Address||Kiryat Hadassah, Minrav Building – Fifth Floor, Jerusalem 9112002, Israel|
|Phone Number||+972 (2) 532-7151.|
|View Prospectus:||Entera Bio Ltd.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-8.28 mil (last 12 months)|
|Price range||$10.00 - $12.00|
|Est. $ Volume||$55.0 mil|
|Manager / Joint Managers||Oppenheimer & Co.|
|Expected To Trade:||1/29/2018|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|